

Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
Pathology: _____ Stage: _____
Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maintenance
ECOG Performance Status: _____ ICD-10 Code: _____
Biomarkers/Characteristics: (Select all that apply)
ALK: __Positive __Negative __Not reported
EGFR: __Mutation __Wild type __Not reported
T790M mutation: __Positive __Negative __Not reported
MET amplification: __Positive __Negative __Not reported
BRAF: __V600E Mutation __V600K Mutation __Wild type __Not reported
PD-L1 expression: __1% to 49% __≥50% __Negative __Not reported
RET gene rearrangement: __Absent __Present __Not reported
Microsatellite instability: __dMMR/MSI-H __MSI-L __Not reported
ROS1 rearrangement: __Positive __Negative __Not reported

Neoadjuvant/Preoperative/Induction Therapy or Adjuvant/Definitive Therapy

Cisplatin and etoposide with concurrent XRT
 Paclitaxel and carboplatin with concurrent XRT

Adjuvant Therapy

Carboplatin and paclitaxel
 Cisplatin and gemcitabine (Gemzar)
 Cisplatin and pemetrexed (Alimta)
 Cisplatin and vinorelbine (Navelbine)

Metastatic Disease | Squamous | ALK/EGFR Negative (ROS Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)*

Metastatic Disease | Squamous | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)*, carboplatin, and paclitaxel

Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)*
 Atezolizumab (Tecentriq)

Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Carboplatin†, pemetrexed (Alimta), and pembrolizumab (Keytruda)

* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate

† In the setting of recurrent/metastatic NSCLC, a substitution of cisplatin for carboplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways (continued)

Metastatic Disease | Squamous or Nonsquamous | Immunotherapy-Ineligible | First Line of Therapy (1st Line) | ECOG PS: 0-2

- Carboplatin† and paclitaxel
- Carboplatin, paclitaxel, and bevacizumab (Avastin) (**NON-SQUAMOUS ONLY**)
- Cisplatin† and gemcitabine (Gemzar)
- Cisplatin† and pemetrexed (Alimta) (**NON-SQUAMOUS ONLY**)

Metastatic Disease | Non-Squamous | Maintenance | ECOG PS: 0-2

- Continuation bevacizumab
- Continuation pemetrexed (Alimta)
- Pembrolizumab (Keytruda)* and pemetrexed (Alimta) (**if previously treated with carboplatin†, pemetrexed, and pembrolizumab**)
- Switch pemetrexed (Alimta)

Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2

- Atezolizumab (Tecentriq) (**if no prior checkpoint inhibitors**)
- Nivolumab (Opdivo) (**if no prior checkpoint inhibitors**)
- Carboplatin† and paclitaxel‡
- Carboplatin† and gemcitabine (Gemzar)‡
- Carboplatin† and pemetrexed (Alimta)‡

Metastatic Disease | ALK Positive | First Line of Therapy (1st Line)

- Alectinib (Alecensa)

Metastatic Disease | EGFR Positive | First Line of Therapy (1st Line)

- Osimertinib (Tagrisso)

Metastatic Disease | ALK or EGFR Positive | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2

- Carboplatin† and paclitaxel
- Cisplatin† and gemcitabine (Gemzar)
- Cisplatin† and pemetrexed (Alimta)

Metastatic Disease | EGFR Positive | ECOG PS: 3-4

- Erlotinib (Tarceva)

* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate

† In the setting of recurrent/metastatic NSCLC, a substitution of cisplatin for carboplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

